On October 19, 2026, Gilead Sciences announced Phase 2 study results showing that its daily 200-milligram oral pill emvistegrast achieved a 23% placebo-adjusted clinical remission rate after 12 weeks in patients with moderate to severe ulcerative colitis. The statistically significant results exceeded Wall Street expectations, addressing an area where most patients fail to achieve remission on existing therapies. Gilead plans to launch Phase 3 trials in 2027 to advance its inflammatory disease pipeline.
Phase 2 trial results for emvistegrast
- ▪In a Phase 2 trial reported on October 19, 2026, a 200-milligram daily dose of Gilead Sciences' emvistegrast taken for 12 weeks achieved a 23% placebo-adjusted clinical remission rate in moderate to severe ulcerative colitis patients.
- ▪The successful Phase 2 results for emvistegrast support Gilead Sciences' effort to advance its clinical pipeline of treatments for inflammatory and autoimmune conditions.
- ▪The Phase 2 clinical trial results for Gilead Sciences' emvistegrast demonstrated statistically significant improvement in ulcerative colitis symptoms that exceeded Wall Street analyst expectations.
Statements from Gilead leadership
- ▪Gilead Sciences senior vice president Swati Tole stated on October 16, 2026, that emvistegrast has the potential to be a best-in-class oral treatment for patients with ulcerative colitis.
- ▪Gilead Sciences senior vice president Swati Tole stated that a majority of patients with inflammatory bowel disease fail to achieve remission and experience persistent symptoms with currently available therapies.
Emvistegrast background and future plans
- ▪Gilead Sciences' emvistegrast is an oral α4β7 inhibitor developed to eliminate symptoms in patients with ulcerative colitis.
- ▪Gilead Sciences plans to begin late-stage Phase 3 clinical trials for emvistegrast in ulcerative colitis in 2027 following positive mid-stage dose-finding trial data.
Story comments
Loading comments…